Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

Current Challenges and Opportunities in Developing Potential Vaccine, Stem Cell and Drug Therapy Candidates: Further Inspection of Therapeutic Options for Coronavirus Disease 2019

Fatemeh Mansouri

Background: Due to the increasing occurrence of novel Coronavirus disease 2019 (COVID-19) among people of different ages around the world, there is an urgent need for an effective medical treatment. Several approaches have been used for controlling and preventing progression of infection in patients, according to their clinical symptoms and laboratory test results in different populations. Exponential growth and poor response to current treatments make it necessary to further examine the novel Coronavirus.

Main body: Here, we presented a brief introduction to the transmission, genomic structure, function, symptoms and clinical tests for COVID-19 in clinics to highlight the most relevant and recent advances in the current approaches for every stage of infection; to evaluate the challenges and opportunities in developing drugs, vaccines and stem cell therapies in clinical trials; and to focus on the role of personalized genomics and medicine in the severity of disease and response to current treatments. The proper selection of a therapeutic option is critical in every stage of infection and can directly affect immune responses to viral infections.

Conclusion: It is necessary for governments, healthcare systems and pharmaceutical companies to concentrate on the use of global communication networks based on population genomics to develop effective drugs and vaccines that can be novel tools for reducing the hospitalization rate and mortality.